At 12:35 pm on Monday, shares of Ajanta Pharma rose 2.16% to Rs 2,683.30, making it one of the top gainers on the Nifty Midcap 150 index. This increase reflects positive investor sentiment towards the stock.
Consolidated Quarterly Financial Performance:
The following table summarizes Ajanta Pharma's consolidated quarterly financial performance:
| Heading | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 1,054.08 Crore | Rs 1,144.92 Crore | Rs 1,186.64 Crore | Rs 1,146.13 Crore | Rs 1,170.41 Crore |
| Net Profit | Rs 202.72 Crore | Rs 245.77 Crore | Rs 216.48 Crore | Rs 232.88 Crore | Rs 225.26 Crore |
| EPS | 16.10 | 19.54 | 17.27 | 18.60 | 18.00 |
Analyzing the quarterly data, Ajanta Pharma's revenue increased by 10.9% from Rs 1,054.08 Crore in March 2024 to Rs 1,170.41 Crore in March 2025. However, there was a slight decrease in net profit, which fell by 6.0% from Rs 245.77 Crore in June 2024 to Rs 225.26 Crore in March 2025. The earnings per share (EPS) also experienced fluctuations, settling at Rs 18.00 for the quarter ending March 2025.
Consolidated Yearly Financial Performance:
The following table presents Ajanta Pharma's consolidated yearly financial performance:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 2,889.69 Crore | Rs 3,340.99 Crore | Rs 3,742.64 Crore | Rs 4,208.71 Crore | Rs 4,648.10 Crore |
| Net Profit | Rs 653.87 Crore | Rs 712.68 Crore | Rs 587.98 Crore | Rs 816.17 Crore | Rs 920.39 Crore |
| EPS | 75.09 | 82.45 | 45.89 | 64.82 | 73.56 |
| BVPS | 344.52 | 380.24 | 268.14 | 282.34 | 302.38 |
| ROE | 21.82 | 21.83 | 17.35 | 22.87 | 24.28 |
| Debt to Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
From the yearly data, the company's revenue saw a substantial increase of 60.8% from Rs 2,889.69 Crore in 2021 to Rs 4,648.10 Crore in 2025. Net profit also rose significantly by 40.7% from Rs 653.87 Crore in 2021 to Rs 920.39 Crore in 2025. The earnings per share (EPS) showed a decrease from Rs 82.45 in 2022 to Rs 73.56 in 2025. Additionally, the return on equity (ROE) improved from 21.82% in 2021 to 24.28% in 2025, while the company maintained a consistent debt-to-equity ratio of 0.00 throughout the period.
Key Financial Ratios:
| Ratio | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 75.09 | 82.45 | 45.89 | 64.82 | 73.56 |
| Diluted Eps (Rs.) | 75.09 | 82.45 | 45.89 | 64.77 | 73.53 |
| Book Value /Share (Rs.) | 344.52 | 380.24 | 268.14 | 282.34 | 302.38 |
| Dividend/Share (Rs.) | 9.50 | 9.50 | 7.00 | 51.00 | 28.00 |
| Face Value | 2 | 2 | 2 | 2 | 2 |
The dividend per share decreased from Rs 51.00 in March 2024 to Rs 28.00 in March 2025. The book value per share also increased from Rs 282.34 to Rs 302.38 during the same time.
Corporate Actions:
Ajanta Pharma has a history of corporate actions, including dividends and bonus issues. The company announced an interim dividend of Rs 28 per share on October 25, 2024, with an effective date of November 6, 2024. Previously, on May 10, 2022, Ajanta Pharma announced a bonus issue with a ratio of 1:2, the ex-bonus date for which was June 22, 2022.
The stock's current price is Rs 2,683.30, with a 2.16% increase, making it a notable gainer in today's trading session.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
